Turja Chakrabarti, MD
Assistant Professor
Medicine
School of Medicine
Dr. Chakrabarti serves as faculty within the UCSF Division of Hospital Medicine, with a primary clinical role on the Hematology-Oncology-BMT Hospitalist Service.
Show full bio (70 words) Hide full bio
His research interests focus on novel therapies for lung cancer. Specifically, he is investigating mechanisms to overcome resistance to targeted therapies in patients with oncogene mutations in lung cancer such as EGFR.
In addition, he is the President & Founder of Pratit International, an organization dedicated to bridging global health disparities with a special focus on vulnerable communities in Kolkata, India.
Awards
Show all (3) Hide
- Alpha Omega Alpha Medical Honor Society, Johns Hopkins University School of Medicine, 2020
- Larry Waterbury MD Award for resident clinical excellence, Johns Hopkins University School of Medicine, 2020
- Gold Humanism Honor Society, Eastern Virginia Medical School, 2016
Education & Training
Show all (5) Hide
- Internal Medicine Chief Residency Johns Hopkins Bayview Medical Center 06/2021
- Internal Medicine Residency Johns Hopkins Bayview Medical Center 06/2020
- MD Doctor of Medicine Eastern Virginia Medical School 05/2017
- MS Physiology & Biophysics Georgetown University 05/2013
- BA Global Health & Societies University of Pennsylvania 05/2012
Interests
Show all (3) Hide
- EGFR mutation
- lung cancer
- Global Health
Publications (2)
Top publication keywords:
Phosphatidylinositol 3-KinasesDisease ProgressionMutationDNA HelicasesImmunotherapyLymphopeniaMaleKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Lung NeoplasmsAgedCarcinoma, Non-Small-Cell LungTranscription FactorsNuclear ProteinsHumans
-
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer discovery 2023 Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, … -
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
Lung cancer (Amsterdam, Netherlands) 2021 Friedes C, Chakrabarti T, Olson S, Prichett L, Brahmer JR, Forde PM, Voong RK, Marrone KA, Lam VK, Hann CL, Broderick SR, Battafarano RJ, Ha JS, Bush EL, Yang SC, Hales RK, Feliciano JL